Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US [Yahoo! Finance]
Intensity Therapeutics, Inc. (INTS)
Company Research
Source: Yahoo! Finance
SHELTON, Conn. March 24, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. , (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, provided an update on its patent portfolio including the recent issuance in December 2025 of a new US patent in the U.S., US Patent Number 12,496,345, entitled "A Method of Treating Cancer". Logo (PRNewsfoto/Intensity Therapeutics Inc.) Lewis H. Bender, Founder, President & CEO, said, "The issuance of this new patent supports the novelty of our unique technology in the U.S. and around the world. The Company now has four U.S. patents and one pending U.S. patent application. We have protection in 41 countries, including our European patent, which is validated in 27 countries. We have registered
Show less
Read more
Impact Snapshot
Event Time:
INTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INTS alerts
High impacting Intensity Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INTS
News
- Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the USPR Newswire
- Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study [Yahoo! Finance]Yahoo! Finance
- Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 StudyPR Newswire
- Intensity Therapeutics regains compliance with Nasdaq's minimum bid price requirement [Seeking Alpha]Seeking Alpha
- Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement [Yahoo! Finance]Yahoo! Finance
INTS
Earnings
- 5/13/25 - Miss
INTS
Sec Filings
- 3/23/26 - Form 8-K
- 3/23/26 - Form 424B5
- 3/6/26 - Form 8-K
- INTS's page on the SEC website